<DOC>
	<DOCNO>NCT01960829</DOCNO>
	<brief_summary>This single-armed , open-labeled single-centered study everolimus selective patient metastatic melanoma evaluation efficacy safety . The study objective evaluate efficacy profile everolimus . The patient comply inclusion exclusion criterion enrol . The estimated recruiting duration 18 month . Everolimus give dose 10 mg orally day lease 6 month unless disease progression intolerance . The follow-up till death ( least 1 year ) .</brief_summary>
	<brief_title>Everolimus Selected Patients With Metastatic Melanoma : Efficacy Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Clinical diagnosis metastasis melanoma . Must evidence mutation ( Kinase domain ) mTOR . Must ECOG performance status 0,1 , 2 . Must estimate life expectancy 3 month great . Must age 18 year old , male female . Must least one measurable site disease define least 1 cm great dimension . Adequate organ function . Must willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Prior systemic therapy metastatic disease within 4 week . Second malignancy within last 5 year . Severe and/or uncontrolled medical disease . Received RAD001 mTOR inhibitor previously . Hypersensitivity everolimus Current treatment another clinical trial . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>TOR Serine-Threonine Kinases</keyword>
</DOC>